H&T Presspart said this week that it acquired the global rights to Hovione Technology‘s capsule-based dry powder inhaler. The company launched a next-gen version of the inhaler called PowdAir Plus at this year’s Respiratory Drug Delivery Europe.
The PowdAir Plus device is made of plastic and its 4-component design lessens manufacturing, assembly and production costs, according to H&T Presspart.
Get the full story at our sister site, Drug Delivery Business News.
The post H&T Presspart, Hovione ink commercialization deal for inhaler tech appeared first on MassDevice.